The treatment of these tumors has recently moved to immunotherapy, but although these drugs often lead to positive results in MSI-H cancer patients, resistance to treatment appears, writes Daily Science, quoted by Discovera.ro. .
"Our therapy is based on exploiting the biological systems of cancer cells (and not healthy tissue)," said Simon Wöhrle, author of this study at the Boehringer Ingelheim Regional Center in Vienna, Austria. "Before we develop new treatments against MSI-H cancer cells, we have to first understand what we are helping them to survive," he added.
The team of researchers has shown that the removal of WRN protein function from MSI-H cells has prevented their proper functioning, resulting in defects in the cell division. "In particular, we found that MSI-H cancer cells without WRN showed chromosome and genome instability, revealing that CCM was vulnerable in the MSI-H cells," said Mark Petronczki, author of another study, Cell Cancer Signs director. Boehringer Ingelheim RCV.
Because WRN's loss of protein is a known cause of Werner syndrome, a disease that causes premature aging associated with an increased risk of tumor development. Unlike the last idea, the current study shows that WRN plays a key role in preventing tumor growth.